A Phase 1B, Open-Label, Dose Escalation with an Expansion Trial of a in Combination with B or a Plus Standard of Care in Patients with Xxx Cancer Eligible for Second Line Treatment

2025-521582-27-00 Protocol LCB-2301-002 Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 3 Jul 2025 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 4 sites · Protocol LCB-2301-002

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 60
Countries 1
Sites 4

XXX CANCER ELIGIBLE FOR SECOND LINE TREATMENT

Key facts

Sponsor
NovImmune S.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
3 Jul 2025 → ongoing
Decision date (initial)
2025-06-30
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

XXX CANCER ELIGIBLE FOR SECOND LINE TREATMENT

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

NovImmune S.A.

Sponsor organisation
NovImmune S.A.
Address
Chemin Du Pre-Fleuri 15
City
Plan-Les-Ouates
Postcode
1228
Country
Switzerland

Scientific contact point

Organisation
NovImmune S.A.
Contact name
Clinical Trial Team

Public contact point

Organisation
NovImmune S.A.
Contact name
Clinical Trial Team

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruitment ended 60 4
Rest of world 0

Investigational sites

Spain

4 sites · Ongoing, recruitment ended
Hospital Universitario Fundacion Jimenez Diaz
Medical Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitario Hm Sanchinarro
Medical Oncology, Calle Ona 10, 28050, Madrid
Clinica Universidad De Navarra
Medical Oncology, Calle Marquesado De Santa Marta 1, 28027, Madrid
Clinica Universidad De Navarra
Medical Oncology, Pio XII Etorbidea 36, 31008, Pamplona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2025-07-03 2025-07-21 2026-01-30

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-03-28 Spain Acceptable
2025-06-30
2025-06-30